Rna Targeting Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
| Property | Value | [1]
|----------|-------| [2]
| Category | Gene-Silencing Therapy | [3]
| Target | mRNA of disease-causing genes | [4]
| Diseases | Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD | [5]
| Stage | Preclinical to FDA-Approved | [6]
RNA-targeting therapies represent a revolutionary approach to treating neurodegenerative diseases by directly targeting the messenger RNA (mRNA) that produces toxic proteins. By reducing the production of disease-causing proteins at their source, these therapies offer the potential for disease modification rather than just symptom management. [7]
| Drug | Target | Disease | Approval Year |
|---|---|---|---|
| Tofersen | SOD1 | ALS | 2023 (accelerated) |
| Nusinersen | SMN2 | Spinal Muscular Atrophy | 2016 |
| Inotersen | TTR | hATTR Polyneuropathy | 2018 |
| Patisiran | TTR | hATTR Polyneuropathy | 2018 |
| Drug | Target | Disease | Phase | NCT Number |
|---|---|---|---|---|
| ASO-C9orf72 | C9orf72 | ALS/FTD | Phase I/II | NCT04931862 |
| ASO-GRN | GRN | FTD | Phase I/II | NCT05547564 |
| ASO-SNCA | SNCA | Parkinson's Disease | Phase I | NCT04165486 |
| ASO-HTT | HTT | Huntington's Disease | Phase I/II | NCT05032196 |
| BIIB080 | MAPT | Alzheimer's Disease | Phase I/II | NCT05399888 |
The study of Rna Targeting Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
For detailed investment analysis, clinical trial pipeline, and key player profiles, see RNA Therapeutics: Investment Landscape Analysis.
Tabrizi SJ, et al. Targeting huntingtin for Huntington's disease. 2019. ↩︎
Benn CL, et al. ASO approaches for neurodegenerative diseases. 2021. ↩︎
Nguyen L, et al. RNA-targeting therapies for ALS and FTD. 2023. ↩︎
Southwell AL, et al. Huntingtin lowering for Huntington's disease. 2022. ↩︎
Swayze EE, et al. Antisense oligonucleotides targeting disease-associated proteins. 2022. ↩︎
Bhattacharya K, et al. siRNA delivery to the brain: progress and challenges. 2021. ↩︎
Khvorova A, et al. RNA targeting in neurological disease. 2024. ↩︎